Developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $141.6M
Founded date: 2016
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.02.2023 | - | $53.6M | - |
| 20.02.2020 | Series B | $88M | Omega Fund... |
Mentions in press and media 12
| Date | Title | Description | Source |
| 10.02.2023 | Spruce Biosciences Announces $53.6 Million Private Placement... | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Feb. 9, 2023– Spruce Biosciences, Inc. (Nasdaq: SPRB), a... | healthcap.... |
| 09.02.2023 | Spruce Biosciences Announces $53.6 Million Private Placement... | South San Francisco, CA — Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical co... | aislingcap... |
| 22.03.2021 | Spruce Biosciences Reports Fourth Quarter and Full Year 2020... | SAN FRANCISCO--(BUSINESS WIRE)--Mar 22, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage... | oaoa.com/n... |
| 17.03.2021 | Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerf... | SAN FRANCISCO--(BUSINESS WIRE)--Mar 17, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage... | oaoa.com/n... |
| 20.02.2020 | Spruce Biosciences Raises $88M in Series B Financing | Spruce Biosciences, a San Francisco, CA-based clinical stage biopharmaceutical company, raised $88m ... | finsmes.co... |
| 20.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing,... | - | abingworth... |
| 20.02.2020 | Spruce nets $88M to push rare disease drug into late-stage t... | In September, Spruce Biosciences reported a phase 2 win for its nonsteroid treatment in a rare endoc... | fiercebiot... |
| 19.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing,... | – Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indica... | aislingcap... |
| - | Spruce Biosciences to Announce Phase 1 and 2 Data of Tildace... | SAN FRANCISCO--(BUSINESS WIRE)--Mar 2, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage ... | oaoa.com/n... |
| - | Spruce Biosciences Strengthens Leadership Team with Appointm... | San Francisco, Calif. – May 6, 2020 – Spruce Biosciences, a late-stage clinical development company ... | healthcap.... |
Show more